O
REGN icon

OppenheimerFunds’s Regeneron Pharmaceuticals REGN Stock Holding History

OppenheimerFunds’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$602K Buy
1,465
+37
+3% +$15.2K ﹤0.01% 1296
2018
Q4 		$533K Sell
1,428
-26
-2% -$9.52K ﹤0.01% 1348
2018
Q3 		$587K Sell
1,454
-267
-16% -$102K ﹤0.01% 1374
2018
Q2 		$594K Sell
1,721
-37,301
-96% -$11.7M ﹤0.01% 1353
2018
Q1 		$13.4M Sell
39,022
-6,596
-14% -$2.29M 0.02% 651
2017
Q4 		$17.2M Sell
45,618
-3,011
-6% -$1.22M 0.02% 629
2017
Q3 		$21.7M Sell
48,629
-7,945
-14% -$3.78M 0.03% 532
2017
Q2 		$27.8M Sell
56,574
-12,349
-18% -$5.4M 0.03% 451
2017
Q1 		$26.7M Buy
68,923
+6,778
+11% +$2.51M 0.03% 485
2016
Q4 		$22.8M Sell
62,145
-78,250
-56% -$29.8M 0.03% 539
2016
Q3 		$56.4M Buy
140,395
+26,974
+24% +$10.8M 0.07% 287
2016
Q2 		$39.6M Buy
113,421
+16,418
+17% +$6.32M 0.05% 374
2016
Q1 		$35M Buy
97,003
+96,196
+11,920% +$39.6M 0.05% 399
2015
Q4 		$441K Buy
+807
New +$437K ﹤0.01% 1334

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

OppenheimerFunds's REGN Position: Q1 2019 in Review

OppenheimerFunds increased its Regeneron Pharmaceuticals (REGN) stake by 2.6% in Q1 2019, buying an estimated $15.2K and bringing the position to 1,465 shares worth $602K. The position accounts for ﹤0.01% of the portfolio, ranked #1296.

OppenheimerFunds first reported a position in REGN in Q4 2015 and has held it in 14 quarters since. The position peaked at $56.4M in Q3 2016. 718 funds tracked by Wall St. Rank hold REGN as of Q1 2019.

  • OppenheimerFunds held 1,465 shares of Regeneron Pharmaceuticals worth $602K as of Q1 2019.
  • OppenheimerFunds bought 37 Regeneron Pharmaceuticals shares in Q1 2019, an estimated $15.2K.
  • Regeneron Pharmaceuticals made up ﹤0.01% of OppenheimerFunds's portfolio in Q1 2019, its #1296 holding.
  • OppenheimerFunds first reported a position in Regeneron Pharmaceuticals in Q4 2015 and has held it in 14 quarters since.
  • OppenheimerFunds's Regeneron Pharmaceuticals position peaked at $56.4M in Q3 2016.
  • 718 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2019.

Based on OppenheimerFunds's 13F filing for Q1 2019, filed 13 May 2019.